. Author manuscript; available in PMC: 2016 Nov 15.

Published in final edited form as: Clin Trials. 2010 Jun 22;7(5):584–596. doi: 10.1177/1740774510373120

Table 4.

Assumed 8-week disease control rate under the null and alternative hypotheses for erlotinib resistant and naïve patients by marker status in the BATTLE-2 design

Under Null Hypothesis
Markers		Erlotinib Naïve				Erlotinib Resistant

M₁	M₂	TX1	TX2	TX3	TX4	TX2	TX3	TX4

−	−	0.3	0.3	0.3	0.3	0.1	0.1	0.1
+	−	0.6	0.6	0.6	0.4	0.2	0.2	0.1
−	+	0.1	0.1	0.1	0.1	0.1	0.1	0.1

Under Alternative Hypothesis

Markers		Erlotinib Naïve				Erlotinib Resistant

M₁	M₂	TX1	TX2	TX3	TX4	TX2	TX3	TX4
−	−	0.3	0.6	0.6	0.6	0.5	0.5	0.5
+	−	0.6	0.9	0.9	0.7	0.6	0.6	0.6
−	+	0.1	0.3	0.3	0.5	0.3	0.3	0.5